DARZALEX SC (Janssen-Cilag Pty Ltd)
Product name
DARZALEX SC
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 (255 working days)
Active ingredients
daratumumab
Registration type
EOI
Indication
DARZALEX SC (solution for injection) in combination with bortezomib, cyclophosphamide and dexamethasone, is now also indicated for the treatment of patients with light chain AL amyloidosis.